NEWS & INSIGHTS

PRECISIONvalue, a Vision Awards finalist, is profiled in the Med Ad News 2021 Healthcare Communications Agencies edition. Learn more about PRECISIONvalue, how they adapted to the unique challenges of 2020, recent accomplishments (including a major rebranding, creation of a dedicated diversity and inclusion initiative, and recruitment and onboarding of high level talent) and future plans.

(more…)

Due to their complexity and cost, developers of cell and gene therapies face unique manufacturing hurdles. Determining the right approach to manufacturing is crucial when bringing these advanced therapeutics from clinical to commercialization.

This white paper, based on a recent webinar co-sponsored by Precision for Medicine and Informa Pharma Intelligence, features the unique expertise of Erin Harris (Editor In Chief of Cell & Gene), David Carr (Director, PRECISIONadvisors), Tony Khoury (Executive Vice President, Project Farma), Janet Lambert (CEO, Alliance for Regenerative Medicine), and Alex Karnal (Partner and Managing Director, Deerfield Management).

(more…)

Increasingly, stakeholders across the healthcare continuum are recognizing the importance of social determinants of health (SDOH) on outcomes and quality of life.

In this white paper from Precision’s Maureen Hennessey, we use the results of a 2019 PRECISIONvalue survey and a subsequent 2020 post-onset of COVID-19 survey to evaluate perspectives on SDOH and assess the progress of programs to address SDOH.

(more…)

Precision Value & Health recently announced the acquisition of Across Health, a Belgium based consultancy specializing in omnichannel strategy within the life-sciences space. Precision’s Carolyn Morgan discusses how Across Health’s proprietary, market-leading Navigator365 product suite will help Precision turbocharge its omnichannel platforms and digital transformation offering.

(more…)

Despite a slew of new branded therapies for acute migraine treatment and migraine prevention, many of which target calcitonin gene-related peptide (CGRP) receptors, drug benefits experts say that health plans and PBMs continue to rely mainly on generic triptans for acute migraine treatment and generic beta-blockers, antiepileptics and tricyclic antidepressants for migraine prevention. Precision’s Jacki Chou joins an expert discussion about developing patient-specific migraine treatment plans and the potential growth of value-based therapies.
(more…)

Inequities in social determinants of health (SDOH) increase the risk of death from COVID-19 for racial and ethnic minority groups. Precision’s Maureen Hennessey identifies steps pharma, health plans, and integrated delivery networks (IDNs) can take to address SDOH to safely establish community immunity.

(more…)

Calculating viral vector yields is essential to determine how much drug product is needed for a specific gene therapy. It’s a critical analysis for any gene therapy organization looking to scale from preclinical to clinical to commercial. Project Farma’s Tony Khoury, Christian Hermanas and Salome Philip provide an in depth review of a valuable yield calculation tool that can serve as a vital prerequisite of the “make vs buy” analysis.

(more…)

Although clinical trials in the cell and gene therapy space have skyrocketed, there’s a significant shortfall in the skilled talent required to execute on the exponential potential of cell and gene therapies. Project Farma and Precision ADVANCE leaders Anshul Mangal and John Khoury discuss the biotherapeutic process and manufacturing talent gap, and propose a multipronged approach to addressing the problem through internal innovation and the external influence of academia and industry associations.

(more…)

The rise of innovative new therapeutic interventions means that payers need more information than ever to properly assess treatments, as well as compare them with existing methods of care. They also can benefit from collaborations with manufacturers, including on innovative pricing models. Precision’s Reta Mourad joins other experts for a discussion of the opportunities and challenges facing payers as they confront antiquated reimbursement models and work to develop new payment models that include therapeutic value assessments.

(more…)

Cancer care has been disproportionately impacted by the COVID-19 pandemic, possibly leading to later-stage cancers and increasing patient morbidity and mortality, as well as regression in the strides made in cancer care and overall patient survival. The oncology ecosystem is determined to do all it can to not only prevent these regressions but also to accelerate further advancements. Precision’s Elizabeth Oyekan outlines 10 observed trends and developments to further optimize cancer care in 2021 and beyond.

(more…)